Macrolides and viral infections: focus on azithromycin in COVID-19 pathology
| Autor: | Marinella Lauriola, Alessandra Romandini, Francesco Scaglione, Arianna Pani |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty Side effect Coronavirus disease 2019 (COVID-19) 030106 microbiology Pneumonia Viral Acute respiratory distress Azithromycin QT interval Antiviral Agents Article 03 medical and health sciences Betacoronavirus 0302 clinical medicine Internal medicine medicine Humans Immunologic Factors Pharmacology (medical) 030212 general & internal medicine Respiratory system Pandemics business.industry SARS-CoV-2 COVID-19 Hydroxychloroquine General Medicine medicine.disease bacterial infections and mycoses Long QT Syndrome Infectious Diseases Middle East respiratory syndrome Drug Therapy Combination business Coronavirus Infections medicine.drug |
| Zdroj: | International Journal of Antimicrobial Agents |
| ISSN: | 0924-8579 |
| DOI: | 10.1016/j.ijantimicag.2020.106053 |
| Popis: | Highlights There is the necessity to quickly find therapeutic options to treat novel SARS-CoV2 Azithromycin has demonstrated to have antiviral and immunomodulatory effects, which could be effective in the hyper-inflammatory syndrome caused by SARS-CoV2 Azithromycin has also shown clinical efficacy in respiratory distress syndrome and in viral infections Preliminary results regarding the efficacy of the combination of azithromycin and hydroxychloroquine in COVID-19 are conflicting There are some concerns regarding the association of azithromycin and hydroxychloroquine because of Qt prolongation Further studies have to be performed to investigate safety and efficacy of azithromycin and the combination with hydroxychloroquine in COVID-19 The emergence of the new disease COVID-19, is posing the challenge of seeking effective therapies. Since the most severe clinical manifestation of COVID-19 appeared to be a severe acute respiratory syndrome, azithromycin has been proposed as a potential treatment. Azithromycin is known to have immunomodulating and antiviral properties. In vitro studies have demonstrated the capacity of azithromycin to reduce production of pro-inflammatory cytokines such as IL-8, IL-6, TNF alpha, reduce oxidative stress and modulate T-helper functions. At the same time there are multiple clinical evidences of the role of azithromycin in acute respiratory distress syndrome and against MERS. Some preliminary evidences have demonstrated controversial results regarding efficacy of azithromycin in combination with hydroxychloroquine in COVID-19. Firstly, a French trial demonstrated 100% of virological negativization of six patients treated with azithromycin plus hydroxychloroquine vs 57.1% of patients treated with only hydroxychloroquine and 12.5% of the control group (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect